Patents by Inventor Jon E. Chatterton

Jon E. Chatterton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20240084252
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 14, 2024
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11851680
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 26, 2023
    Assignee: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20230279349
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: August 17, 2022
    Publication date: September 7, 2023
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20220364097
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: June 15, 2022
    Publication date: November 17, 2022
    Inventors: Jon E. Chatterton, David P. Bingaman
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11453861
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: September 27, 2022
    Assignee: PRECISION BIOSCIENCES, INC.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11384335
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: July 12, 2022
    Assignee: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20220204929
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 30, 2022
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20220162614
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 26, 2022
    Inventors: Jon E. Chatterton, David P. Bingaman
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20220042021
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: October 20, 2021
    Publication date: February 10, 2022
    Inventors: Jon E. Chatterton, David P. Bingaman
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20220041987
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: October 26, 2021
    Publication date: February 10, 2022
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11186822
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: November 30, 2021
    Assignee: PRECISION BIOSCIENCES, INC.
    Inventors: Aaron Martin, Jon E. Chatterton
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20210254002
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 19, 2021
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20210230603
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: April 7, 2021
    Publication date: July 29, 2021
    Inventors: Jon E. Chatterton, David P. Bingaman
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11008548
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: May 18, 2021
    Assignee: PRECISION BIOSCIENCES, INC.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20210108206
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: December 8, 2020
    Publication date: April 15, 2021
    Inventors: Jon E. Chatterton, David P. Bingaman
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20200392508
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 17, 2020
    Inventors: Jon E. Chatterton, David P. Bingaman
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20200370014
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: June 22, 2020
    Publication date: November 26, 2020
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20200277608
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Jon E. Chatterton, David P. Bingaman
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20200165615
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 28, 2020
    Inventors: Jon E. Chatterton, David P. Bingaman
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20200048637
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: October 29, 2019
    Publication date: February 13, 2020
    Inventors: Jon E. Chatterton, David P. Bingaman